PoplarV1, Main, Exploration, bibRecord, 001557

A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.

Identifieur interne : 001557 ( Main/Exploration ); précédent : 001556; suivant : 001558

A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.

Auteurs : Kazuki Takada [Japon] ; Gouji Toyokawa [Japon] ; Tatsuro Okamoto [Japon] ; Mototsugu Shimokawa [Japon] ; Yuka Kozuma [Japon] ; Taichi Matsubara [Japon] ; Naoki Haratake [Japon] ; Takaki Akamine [Japon] ; Shinkichi Takamori [Japon] ; Masakazu Katsura [Japon] ; Fumihiro Shoji [Japon] ; Yoshinao Oda [Japon] ; Yoshihiko Maehara [Japon]

Source :

Clinical lung cancer [ 1938-0690 ] ; 2017.

RBID : pubmed:28318951

Descripteurs français

English descriptors

KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antibodies (metabolism), Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (MeSH), Antineoplastic Agents, Immunological (therapeutic use), B7-H1 Antigen (metabolism), Blood Vessels (pathology), Carcinoma, Non-Small-Cell Lung (drug therapy), Carcinoma, Non-Small-Cell Lung (genetics), Carcinoma, Non-Small-Cell Lung (metabolism), Carcinoma, Non-Small-Cell Lung (pathology), Carcinoma, Squamous Cell (pathology), Clinical Trials, Phase II as Topic (MeSH), Clinical Trials, Phase III as Topic (MeSH), Disease-Free Survival (MeSH), ErbB Receptors (genetics), Female (MeSH), Humans (MeSH), Immunohistochemistry (MeSH), Lung Neoplasms (drug therapy), Lung Neoplasms (genetics), Lung Neoplasms (metabolism), Lung Neoplasms (pathology), Male (MeSH), Middle Aged (MeSH), Neoplasm Invasiveness (MeSH), Neoplasm Staging (MeSH), Predictive Value of Tests (MeSH), Retrospective Studies (MeSH), Sex Factors (MeSH), Smoking (MeSH), Survival Rate (MeSH).
MESH :
- chemical , genetics : ErbB Receptors.
- chemical , metabolism : Antibodies, B7-H1 Antigen.
- chemical , therapeutic use : Antibodies, Monoclonal, Antineoplastic Agents, Immunological.
- drug therapy : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- genetics : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- metabolism : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- pathology : Blood Vessels, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms.
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Disease-Free Survival, Female, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Predictive Value of Tests, Retrospective Studies, Sex Factors, Smoking, Survival Rate.

Abstract

BACKGROUND

Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have been identified as novel targets for immunotherapy, with anti-PD-1 therapy currently the standard treatment for non-small-cell lung cancer (NSCLC) patients after the failure of first-line chemotherapy treatment. The recent phase II POPLAR and phase III OAK studies showed that atezolizumab, a representative PD-L1 inhibitor, exhibited a survival benefit compared with standard therapy in patients with NSCLC.

PATIENTS AND METHODS

We examined PD-L1 expression in NSCLC using the clone SP142 of POPLAR and OAK studies. PD-L1 expression in 499 surgically resected NSCLC patients was evaluated using immunohistochemistry using SP142. We set cutoff values as 1%, 5%, 10%, and 50%.

RESULTS

The samples from 189 (37.9%), 119 (23.8%), 71 (14.2%), and 39 (7.8%) patients were positive for PD-L1 expression at cutoff values of 1%, 5%, 10%, and 50%, respectively. Fisher exact tests showed that PD-L1 positivity was significantly associated with male sex, smoking, advanced stage, the presence of vascular invasion, squamous cell carcinoma, and wild type epidermal growth factor receptor gene mutation status at all cutoff values. Univariate and multivariate survival analyses revealed that PD-L1-positive patients had a worse prognosis than PD-L1-negative patients only at the 1% cutoff value. Forest plot analyses showed that the 1% cutoff provided a more sensitive value for the prediction of postoperative prognosis.

CONCLUSION

PD-L1 expression varied greatly according to different cutoff values. This study might be a useful reference to understand the results of POPLAR and OAK studies and to select patients likely to benefit from atezolizumab.

DOI: 10.1016/j.cllc.2017.02.004
PubMed: 28318951

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001403
to stream Main, to step Curation: 001403

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.</title>
<author><name sortKey="Takada, Kazuki" sort="Takada, Kazuki" uniqKey="Takada K" first="Kazuki" last="Takada">Kazuki Takada</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Toyokawa, Gouji" sort="Toyokawa, Gouji" uniqKey="Toyokawa G" first="Gouji" last="Toyokawa">Gouji Toyokawa</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: gouji104kawa@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Okamoto, Tatsuro" sort="Okamoto, Tatsuro" uniqKey="Okamoto T" first="Tatsuro" last="Okamoto">Tatsuro Okamoto</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shimokawa, Mototsugu" sort="Shimokawa, Mototsugu" uniqKey="Shimokawa M" first="Mototsugu" last="Shimokawa">Mototsugu Shimokawa</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Clinical Research Institute, National Kyushu Cancer Center, Fukuoka</wicri:regionArea>
<wicri:noRegion>Fukuoka</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kozuma, Yuka" sort="Kozuma, Yuka" uniqKey="Kozuma Y" first="Yuka" last="Kozuma">Yuka Kozuma</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Matsubara, Taichi" sort="Matsubara, Taichi" uniqKey="Matsubara T" first="Taichi" last="Matsubara">Taichi Matsubara</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haratake, Naoki" sort="Haratake, Naoki" uniqKey="Haratake N" first="Naoki" last="Haratake">Naoki Haratake</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Akamine, Takaki" sort="Akamine, Takaki" uniqKey="Akamine T" first="Takaki" last="Akamine">Takaki Akamine</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Takamori, Shinkichi" sort="Takamori, Shinkichi" uniqKey="Takamori S" first="Shinkichi" last="Takamori">Shinkichi Takamori</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Katsura, Masakazu" sort="Katsura, Masakazu" uniqKey="Katsura M" first="Masakazu" last="Katsura">Masakazu Katsura</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shoji, Fumihiro" sort="Shoji, Fumihiro" uniqKey="Shoji F" first="Fumihiro" last="Shoji">Fumihiro Shoji</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oda, Yoshinao" sort="Oda, Yoshinao" uniqKey="Oda Y" first="Yoshinao" last="Oda">Yoshinao Oda</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Maehara, Yoshihiko" sort="Maehara, Yoshihiko" uniqKey="Maehara Y" first="Yoshihiko" last="Maehara">Yoshihiko Maehara</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28318951</idno>
<idno type="pmid">28318951</idno>
<idno type="doi">10.1016/j.cllc.2017.02.004</idno>
<idno type="wicri:Area/Main/Corpus">001403</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001403</idno>
<idno type="wicri:Area/Main/Curation">001403</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001403</idno>
<idno type="wicri:Area/Main/Exploration">001403</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.</title>
<author><name sortKey="Takada, Kazuki" sort="Takada, Kazuki" uniqKey="Takada K" first="Kazuki" last="Takada">Kazuki Takada</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Toyokawa, Gouji" sort="Toyokawa, Gouji" uniqKey="Toyokawa G" first="Gouji" last="Toyokawa">Gouji Toyokawa</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: gouji104kawa@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Okamoto, Tatsuro" sort="Okamoto, Tatsuro" uniqKey="Okamoto T" first="Tatsuro" last="Okamoto">Tatsuro Okamoto</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shimokawa, Mototsugu" sort="Shimokawa, Mototsugu" uniqKey="Shimokawa M" first="Mototsugu" last="Shimokawa">Mototsugu Shimokawa</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Clinical Research Institute, National Kyushu Cancer Center, Fukuoka</wicri:regionArea>
<wicri:noRegion>Fukuoka</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kozuma, Yuka" sort="Kozuma, Yuka" uniqKey="Kozuma Y" first="Yuka" last="Kozuma">Yuka Kozuma</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Matsubara, Taichi" sort="Matsubara, Taichi" uniqKey="Matsubara T" first="Taichi" last="Matsubara">Taichi Matsubara</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haratake, Naoki" sort="Haratake, Naoki" uniqKey="Haratake N" first="Naoki" last="Haratake">Naoki Haratake</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Akamine, Takaki" sort="Akamine, Takaki" uniqKey="Akamine T" first="Takaki" last="Akamine">Takaki Akamine</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Takamori, Shinkichi" sort="Takamori, Shinkichi" uniqKey="Takamori S" first="Shinkichi" last="Takamori">Shinkichi Takamori</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Katsura, Masakazu" sort="Katsura, Masakazu" uniqKey="Katsura M" first="Masakazu" last="Katsura">Masakazu Katsura</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shoji, Fumihiro" sort="Shoji, Fumihiro" uniqKey="Shoji F" first="Fumihiro" last="Shoji">Fumihiro Shoji</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oda, Yoshinao" sort="Oda, Yoshinao" uniqKey="Oda Y" first="Yoshinao" last="Oda">Yoshinao Oda</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Maehara, Yoshihiko" sort="Maehara, Yoshihiko" uniqKey="Maehara Y" first="Yoshihiko" last="Maehara">Yoshihiko Maehara</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka</wicri:regionArea>
<orgName type="university">Université de Kyūshū</orgName>
<placeName><settlement type="city">Fukuoka</settlement>
<region type="province">Kyūshū</region>
<region type="prefecture">Préfecture de Fukuoka</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical lung cancer</title>
<idno type="eISSN">1938-0690</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Antibodies (metabolism)</term>
<term>Antibodies, Monoclonal (therapeutic use)</term>
<term>Antibodies, Monoclonal, Humanized (MeSH)</term>
<term>Antineoplastic Agents, Immunological (therapeutic use)</term>
<term>B7-H1 Antigen (metabolism)</term>
<term>Blood Vessels (pathology)</term>
<term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term>
<term>Carcinoma, Non-Small-Cell Lung (genetics)</term>
<term>Carcinoma, Non-Small-Cell Lung (metabolism)</term>
<term>Carcinoma, Non-Small-Cell Lung (pathology)</term>
<term>Carcinoma, Squamous Cell (pathology)</term>
<term>Clinical Trials, Phase II as Topic (MeSH)</term>
<term>Clinical Trials, Phase III as Topic (MeSH)</term>
<term>Disease-Free Survival (MeSH)</term>
<term>ErbB Receptors (genetics)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunohistochemistry (MeSH)</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (genetics)</term>
<term>Lung Neoplasms (metabolism)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Neoplasm Invasiveness (MeSH)</term>
<term>Neoplasm Staging (MeSH)</term>
<term>Predictive Value of Tests (MeSH)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Sex Factors (MeSH)</term>
<term>Smoking (MeSH)</term>
<term>Survival Rate (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Anticorps (métabolisme)</term>
<term>Anticorps monoclonaux (usage thérapeutique)</term>
<term>Anticorps monoclonaux humanisés (MeSH)</term>
<term>Antigène CD274 (métabolisme)</term>
<term>Antinéoplasiques immunologiques (usage thérapeutique)</term>
<term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term>
<term>Carcinome pulmonaire non à petites cellules (génétique)</term>
<term>Carcinome pulmonaire non à petites cellules (métabolisme)</term>
<term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term>
<term>Carcinome épidermoïde (anatomopathologie)</term>
<term>Essais cliniques de phase II comme sujet (MeSH)</term>
<term>Essais cliniques de phase III comme sujet (MeSH)</term>
<term>Facteurs sexuels (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Fumer (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Immunohistochimie (MeSH)</term>
<term>Invasion tumorale (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Récepteurs ErbB (génétique)</term>
<term>Stadification tumorale (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Survie sans rechute (MeSH)</term>
<term>Taux de survie (MeSH)</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (génétique)</term>
<term>Tumeurs du poumon (métabolisme)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
<term>Vaisseaux sanguins (anatomopathologie)</term>
<term>Valeur prédictive des tests (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>ErbB Receptors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antibodies</term>
<term>B7-H1 Antigen</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antineoplastic Agents, Immunological</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term>
<term>Carcinome épidermoïde</term>
<term>Tumeurs du poumon</term>
<term>Vaisseaux sanguins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term>
<term>Récepteurs ErbB</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Anticorps</term>
<term>Antigène CD274</term>
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Blood Vessels</term>
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>Carcinoma, Squamous Cell</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Antinéoplasiques immunologiques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Clinical Trials, Phase II as Topic</term>
<term>Clinical Trials, Phase III as Topic</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasm Invasiveness</term>
<term>Neoplasm Staging</term>
<term>Predictive Value of Tests</term>
<term>Retrospective Studies</term>
<term>Sex Factors</term>
<term>Smoking</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Essais cliniques de phase II comme sujet</term>
<term>Essais cliniques de phase III comme sujet</term>
<term>Facteurs sexuels</term>
<term>Femelle</term>
<term>Fumer</term>
<term>Humains</term>
<term>Immunohistochimie</term>
<term>Invasion tumorale</term>
<term>Mâle</term>
<term>Stadification tumorale</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
<term>Taux de survie</term>
<term>Valeur prédictive des tests</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have been identified as novel targets for immunotherapy, with anti-PD-1 therapy currently the standard treatment for non-small-cell lung cancer (NSCLC) patients after the failure of first-line chemotherapy treatment. The recent phase II POPLAR and phase III OAK studies showed that atezolizumab, a representative PD-L1 inhibitor, exhibited a survival benefit compared with standard therapy in patients with NSCLC.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>PATIENTS AND METHODS</b>
</p>
<p>We examined PD-L1 expression in NSCLC using the clone SP142 of POPLAR and OAK studies. PD-L1 expression in 499 surgically resected NSCLC patients was evaluated using immunohistochemistry using SP142. We set cutoff values as 1%, 5%, 10%, and 50%.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>The samples from 189 (37.9%), 119 (23.8%), 71 (14.2%), and 39 (7.8%) patients were positive for PD-L1 expression at cutoff values of 1%, 5%, 10%, and 50%, respectively. Fisher exact tests showed that PD-L1 positivity was significantly associated with male sex, smoking, advanced stage, the presence of vascular invasion, squamous cell carcinoma, and wild type epidermal growth factor receptor gene mutation status at all cutoff values. Univariate and multivariate survival analyses revealed that PD-L1-positive patients had a worse prognosis than PD-L1-negative patients only at the 1% cutoff value. Forest plot analyses showed that the 1% cutoff provided a more sensitive value for the prediction of postoperative prognosis.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>PD-L1 expression varied greatly according to different cutoff values. This study might be a useful reference to understand the results of POPLAR and OAK studies and to select patients likely to benefit from atezolizumab.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28318951</PMID>
<DateCompleted><Year>2018</Year>
<Month>02</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-0690</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>5</Issue>
<PubDate><Year>2017</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>Clinical lung cancer</Title>
<ISOAbbreviation>Clin Lung Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.</ArticleTitle>
<Pagination><MedlinePgn>572-582.e1</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1525-7304(17)30047-5</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cllc.2017.02.004</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have been identified as novel targets for immunotherapy, with anti-PD-1 therapy currently the standard treatment for non-small-cell lung cancer (NSCLC) patients after the failure of first-line chemotherapy treatment. The recent phase II POPLAR and phase III OAK studies showed that atezolizumab, a representative PD-L1 inhibitor, exhibited a survival benefit compared with standard therapy in patients with NSCLC.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS">We examined PD-L1 expression in NSCLC using the clone SP142 of POPLAR and OAK studies. PD-L1 expression in 499 surgically resected NSCLC patients was evaluated using immunohistochemistry using SP142. We set cutoff values as 1%, 5%, 10%, and 50%.</AbstractText>
<AbstractText Label="RESULTS">The samples from 189 (37.9%), 119 (23.8%), 71 (14.2%), and 39 (7.8%) patients were positive for PD-L1 expression at cutoff values of 1%, 5%, 10%, and 50%, respectively. Fisher exact tests showed that PD-L1 positivity was significantly associated with male sex, smoking, advanced stage, the presence of vascular invasion, squamous cell carcinoma, and wild type epidermal growth factor receptor gene mutation status at all cutoff values. Univariate and multivariate survival analyses revealed that PD-L1-positive patients had a worse prognosis than PD-L1-negative patients only at the 1% cutoff value. Forest plot analyses showed that the 1% cutoff provided a more sensitive value for the prediction of postoperative prognosis.</AbstractText>
<AbstractText Label="CONCLUSION">PD-L1 expression varied greatly according to different cutoff values. This study might be a useful reference to understand the results of POPLAR and OAK studies and to select patients likely to benefit from atezolizumab.</AbstractText>
<CopyrightInformation>Copyright © 2017 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takada</LastName>
<ForeName>Kazuki</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Toyokawa</LastName>
<ForeName>Gouji</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: gouji104kawa@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Okamoto</LastName>
<ForeName>Tatsuro</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shimokawa</LastName>
<ForeName>Mototsugu</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kozuma</LastName>
<ForeName>Yuka</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Matsubara</LastName>
<ForeName>Taichi</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Haratake</LastName>
<ForeName>Naoki</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Akamine</LastName>
<ForeName>Takaki</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Takamori</LastName>
<ForeName>Shinkichi</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Katsura</LastName>
<ForeName>Masakazu</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shoji</LastName>
<ForeName>Fumihiro</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Oda</LastName>
<ForeName>Yoshinao</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Maehara</LastName>
<ForeName>Yoshihiko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>03</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Lung Cancer</MedlineTA>
<NlmUniqueID>100893225</NlmUniqueID>
<ISSNLinking>1525-7304</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>52CMI0WC3Y</RegistryNumber>
<NameOfSubstance UI="C000594389">atezolizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001808" MajorTopicYN="N">Blood Vessels</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Immunohistochemistry</Keyword>
<Keyword MajorTopicYN="Y">Immunotherapy</Keyword>
<Keyword MajorTopicYN="Y">Lung cancer</Keyword>
<Keyword MajorTopicYN="Y">Programmed cell death ligand-1</Keyword>
<Keyword MajorTopicYN="Y">Programmed cell death-1</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>12</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>02</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>02</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>2</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28318951</ArticleId>
<ArticleId IdType="pii">S1525-7304(17)30047-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.cllc.2017.02.004</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Japon</li>
</country>
<region><li>Kyūshū</li>
<li>Préfecture de Fukuoka</li>
</region>
<settlement><li>Fukuoka</li>
</settlement>
<orgName><li>Université de Kyūshū</li>
</orgName>
</list>
<tree><country name="Japon"><region name="Kyūshū"><name sortKey="Takada, Kazuki" sort="Takada, Kazuki" uniqKey="Takada K" first="Kazuki" last="Takada">Kazuki Takada</name>
</region>
<name sortKey="Akamine, Takaki" sort="Akamine, Takaki" uniqKey="Akamine T" first="Takaki" last="Akamine">Takaki Akamine</name>
<name sortKey="Haratake, Naoki" sort="Haratake, Naoki" uniqKey="Haratake N" first="Naoki" last="Haratake">Naoki Haratake</name>
<name sortKey="Katsura, Masakazu" sort="Katsura, Masakazu" uniqKey="Katsura M" first="Masakazu" last="Katsura">Masakazu Katsura</name>
<name sortKey="Kozuma, Yuka" sort="Kozuma, Yuka" uniqKey="Kozuma Y" first="Yuka" last="Kozuma">Yuka Kozuma</name>
<name sortKey="Maehara, Yoshihiko" sort="Maehara, Yoshihiko" uniqKey="Maehara Y" first="Yoshihiko" last="Maehara">Yoshihiko Maehara</name>
<name sortKey="Matsubara, Taichi" sort="Matsubara, Taichi" uniqKey="Matsubara T" first="Taichi" last="Matsubara">Taichi Matsubara</name>
<name sortKey="Oda, Yoshinao" sort="Oda, Yoshinao" uniqKey="Oda Y" first="Yoshinao" last="Oda">Yoshinao Oda</name>
<name sortKey="Okamoto, Tatsuro" sort="Okamoto, Tatsuro" uniqKey="Okamoto T" first="Tatsuro" last="Okamoto">Tatsuro Okamoto</name>
<name sortKey="Shimokawa, Mototsugu" sort="Shimokawa, Mototsugu" uniqKey="Shimokawa M" first="Mototsugu" last="Shimokawa">Mototsugu Shimokawa</name>
<name sortKey="Shoji, Fumihiro" sort="Shoji, Fumihiro" uniqKey="Shoji F" first="Fumihiro" last="Shoji">Fumihiro Shoji</name>
<name sortKey="Takamori, Shinkichi" sort="Takamori, Shinkichi" uniqKey="Takamori S" first="Shinkichi" last="Takamori">Shinkichi Takamori</name>
<name sortKey="Toyokawa, Gouji" sort="Toyokawa, Gouji" uniqKey="Toyokawa G" first="Gouji" last="Toyokawa">Gouji Toyokawa</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001557 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001557 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    PoplarV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28318951
   |texte=   A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28318951" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PoplarV1

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 12:07:19 2020. Site generation: Wed Nov 18 12:16:31 2020

	Serveur d'exploration sur le peuplier
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le peuplier

A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.

A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki